nature-reviews-drug-discovery
Nature Reviews Drug Discovery (nature-reviews-drug-discovery)
Journal positioning
Nature Reviews Drug Discovery is a Springer Nature title and the field-defining review journal for drug discovery and development. Its defining character is authoritative, commissioned synthesis: it publishes no primary research, and the great majority of content is solicited by the editors from leaders in pharmacology, medicinal chemistry, translational medicine, and pharma R&D strategy. The journal rewards reviews and analyses that frame where a therapeutic area, target class, or development paradigm stands and where it is heading — integrating mechanism, clinical evidence, pipeline landscape, and commercial and regulatory context — rather than narrow methodological updates. Readership spans academic pharmacologists, biotech and pharma scientists, clinicians, and investors. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Because most articles are commissioned, an unsolicited submission almost always begins with a pre-submission proposal. Before submitting, re-check the live author instructions on the Nature Reviews Drug Discovery site.
When to trigger
- The author is preparing a commissioned or proposed review on a drug target, modality, therapeutic area, or aspect of pharma R&D and names this journal as the venue.
- A manuscript synthesizes the state of drug discovery or development for a field — integrating biology, clinical data, and pipeline landscape — and the author is choosing between this journal and Nature Medicine, Nature Reviews Methods Primers, or Cell Reports Medicine.
- The author has a primary-research drug-discovery study and needs to be redirected, because this journal publishes no original data.
- The author needs the journal's commissioning norms, scope boundaries, and desk-reject criteria before drafting a proposal.